Sino-American Tianjin SmithKline & French Laboratories
A pharmaceutical joint venture in Tianjin, China, known as Sino-American Tianjin SmithKline & French Laboratories.
Last updated November 4, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Sino-American Tianjin SmithKline & French Laboratories (abbreviated as Sino-American SK&F) is a pharmaceutical joint venture in the People's Republic of China, headquartered in Tianjin. Its joint venture parties are Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Tianjin Pharmaceutical Group Co., Ltd., and the American company SmithKline Beecham. Its brands include Contac (compound pseudoephedrine hydrochloride sustained-release capsules), Fenbid (ibuprofen), Bactroban (mupirocin), SK&F Zental (albendazole), and Polident.
History
Sino-American Tianjin SmithKline & French Laboratories (abbreviated as Sino-American SK&F) is a pharmaceutical joint venture in the People's Republic of China, established with the United Kingdom (originally the United States at the time of founding), headquartered in Tianjin. The joint venture parties are Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Tianjin Pharmaceutical Group Co., Ltd., and the American company SmithKline Beecham.
Sino-American Tianjin SmithKline & French Laboratories was established as a joint venture between Chinese parties (Tianjin Zhongxin Pharmaceutical Group and Tianjin Pharmaceutical Group) and the American company SmithKline Beecham.
Products and positioning
Contac (compound pseudoephedrine hydrochloride sustained-release capsules)
Fenbid (ibuprofen)
Bactroban (mupirocin)
SK&F Zental (albendazole)
Polident
Controversies
2000
PPA controversy: Contac suspended, losses about RMB 600 million
In November 2000, China's drug regulator, because phenylpropanolamine (PPA) may increase the risk of hemorrhagic stroke, required suspension of use and sale of PPA-containing drugs. Sino-American SmithKline immediately stopped selling Contac and Kangde and recalled drugs from channels, with direct losses of about RMB 600 million; in 2001 it launched "New Contac" replacing PPA with PSE, and its crisis PR was regarded as a classic case. Sales suspension and recall.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sino-american-tianjin-smithkline-and-french-laboratories · Editorial policy · How profiles are compiled